Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis

Min Su Kim, Audrey Horst, Steven Blinka, Karl Stamm, Donna Mahnke, James Schuman, Rebekah Gundry, Aoy Tomita-Mitchell, John Lough

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage. Although direct activation of the Activin-A and/or Bmp pathways with growth factors yields context-dependent success, recent studies have shown that induction of Wnt signaling using low molecular weight molecules such as CHIR, which in turn induces the Activin-A and Bmp pathways, is widely effective. To further enhance the reproducibility of CHIR-induced cardiomyogenesis, and to ultimately promote myocyte maturation, we are using exogenous growth factors to optimize cardiomyogenic signaling downstream of CHIR induction. As indicated by RNA-seq, induction with CHIR during Day 1 (Days 0-1) was followed by immediate expression of Nodal ligands and receptors, followed later by Bmp ligands and receptors. Co-induction with CHIR and high levels of the Nodal mimetic Activin-A (50-100 ng/ml) during Day 0-1 efficiently induced definitive endoderm, whereas CHIR supplemented with Activin-A at low levels (10 ng/ml) consistently improved cardiomyogenic efficiency, even when CHIR alone was ineffective. Moreover, co-induction using CHIR and low levels of Activin-A apparently increased the rate of cardiomyogenesis, as indicated by the initial appearance of rhythmically beating cells by Day 6 instead of Day 8. By contrast, co-induction with CHIR plus low levels (3-10 ng/ml) of Bmp4 during Day 0-1 consistently and strongly inhibited cardiomyogenesis. These findings, which demonstrate that cardiomyogenic efficacy is improved by optimizing levels of CHIR-induced growth factors when applied in accord with their sequence of endogenous expression, are consistent with the idea that Nodal (Activin-A) levels toggle the entry of cells into the endodermal or mesodermal lineages, while Bmp levels regulate subsequent allocation into mesodermal cell types.

Original languageEnglish (US)
Article numbere0118670
JournalPloS one
Volume10
Issue number2
DOIs
StatePublished - Feb 23 2015

Fingerprint

activins
Specifications
growth factors
Intercellular Signaling Peptides and Proteins
cells
Ligands
Endoderm
receptors
Drug Design
heart diseases
reproducibility
myocytes
Muscle Cells
activin A
Heart Diseases
Molecular Weight
Chemical activation
Molecular weight
RNA
molecular weight

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Kim, M. S., Horst, A., Blinka, S., Stamm, K., Mahnke, D., Schuman, J., ... Lough, J. (2015). Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis. PloS one, 10(2), [e0118670]. https://doi.org/10.1371/journal.pone.0118670

Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis. / Kim, Min Su; Horst, Audrey; Blinka, Steven; Stamm, Karl; Mahnke, Donna; Schuman, James; Gundry, Rebekah; Tomita-Mitchell, Aoy; Lough, John.

In: PloS one, Vol. 10, No. 2, e0118670, 23.02.2015.

Research output: Contribution to journalArticle

Kim, MS, Horst, A, Blinka, S, Stamm, K, Mahnke, D, Schuman, J, Gundry, R, Tomita-Mitchell, A & Lough, J 2015, 'Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis', PloS one, vol. 10, no. 2, e0118670. https://doi.org/10.1371/journal.pone.0118670
Kim, Min Su ; Horst, Audrey ; Blinka, Steven ; Stamm, Karl ; Mahnke, Donna ; Schuman, James ; Gundry, Rebekah ; Tomita-Mitchell, Aoy ; Lough, John. / Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis. In: PloS one. 2015 ; Vol. 10, No. 2.
@article{35b7c383a46940a28dcf0fe40d732432,
title = "Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis",
abstract = "The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage. Although direct activation of the Activin-A and/or Bmp pathways with growth factors yields context-dependent success, recent studies have shown that induction of Wnt signaling using low molecular weight molecules such as CHIR, which in turn induces the Activin-A and Bmp pathways, is widely effective. To further enhance the reproducibility of CHIR-induced cardiomyogenesis, and to ultimately promote myocyte maturation, we are using exogenous growth factors to optimize cardiomyogenic signaling downstream of CHIR induction. As indicated by RNA-seq, induction with CHIR during Day 1 (Days 0-1) was followed by immediate expression of Nodal ligands and receptors, followed later by Bmp ligands and receptors. Co-induction with CHIR and high levels of the Nodal mimetic Activin-A (50-100 ng/ml) during Day 0-1 efficiently induced definitive endoderm, whereas CHIR supplemented with Activin-A at low levels (10 ng/ml) consistently improved cardiomyogenic efficiency, even when CHIR alone was ineffective. Moreover, co-induction using CHIR and low levels of Activin-A apparently increased the rate of cardiomyogenesis, as indicated by the initial appearance of rhythmically beating cells by Day 6 instead of Day 8. By contrast, co-induction with CHIR plus low levels (3-10 ng/ml) of Bmp4 during Day 0-1 consistently and strongly inhibited cardiomyogenesis. These findings, which demonstrate that cardiomyogenic efficacy is improved by optimizing levels of CHIR-induced growth factors when applied in accord with their sequence of endogenous expression, are consistent with the idea that Nodal (Activin-A) levels toggle the entry of cells into the endodermal or mesodermal lineages, while Bmp levels regulate subsequent allocation into mesodermal cell types.",
author = "Kim, {Min Su} and Audrey Horst and Steven Blinka and Karl Stamm and Donna Mahnke and James Schuman and Rebekah Gundry and Aoy Tomita-Mitchell and John Lough",
year = "2015",
month = "2",
day = "23",
doi = "10.1371/journal.pone.0118670",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis

AU - Kim, Min Su

AU - Horst, Audrey

AU - Blinka, Steven

AU - Stamm, Karl

AU - Mahnke, Donna

AU - Schuman, James

AU - Gundry, Rebekah

AU - Tomita-Mitchell, Aoy

AU - Lough, John

PY - 2015/2/23

Y1 - 2015/2/23

N2 - The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage. Although direct activation of the Activin-A and/or Bmp pathways with growth factors yields context-dependent success, recent studies have shown that induction of Wnt signaling using low molecular weight molecules such as CHIR, which in turn induces the Activin-A and Bmp pathways, is widely effective. To further enhance the reproducibility of CHIR-induced cardiomyogenesis, and to ultimately promote myocyte maturation, we are using exogenous growth factors to optimize cardiomyogenic signaling downstream of CHIR induction. As indicated by RNA-seq, induction with CHIR during Day 1 (Days 0-1) was followed by immediate expression of Nodal ligands and receptors, followed later by Bmp ligands and receptors. Co-induction with CHIR and high levels of the Nodal mimetic Activin-A (50-100 ng/ml) during Day 0-1 efficiently induced definitive endoderm, whereas CHIR supplemented with Activin-A at low levels (10 ng/ml) consistently improved cardiomyogenic efficiency, even when CHIR alone was ineffective. Moreover, co-induction using CHIR and low levels of Activin-A apparently increased the rate of cardiomyogenesis, as indicated by the initial appearance of rhythmically beating cells by Day 6 instead of Day 8. By contrast, co-induction with CHIR plus low levels (3-10 ng/ml) of Bmp4 during Day 0-1 consistently and strongly inhibited cardiomyogenesis. These findings, which demonstrate that cardiomyogenic efficacy is improved by optimizing levels of CHIR-induced growth factors when applied in accord with their sequence of endogenous expression, are consistent with the idea that Nodal (Activin-A) levels toggle the entry of cells into the endodermal or mesodermal lineages, while Bmp levels regulate subsequent allocation into mesodermal cell types.

AB - The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage. Although direct activation of the Activin-A and/or Bmp pathways with growth factors yields context-dependent success, recent studies have shown that induction of Wnt signaling using low molecular weight molecules such as CHIR, which in turn induces the Activin-A and Bmp pathways, is widely effective. To further enhance the reproducibility of CHIR-induced cardiomyogenesis, and to ultimately promote myocyte maturation, we are using exogenous growth factors to optimize cardiomyogenic signaling downstream of CHIR induction. As indicated by RNA-seq, induction with CHIR during Day 1 (Days 0-1) was followed by immediate expression of Nodal ligands and receptors, followed later by Bmp ligands and receptors. Co-induction with CHIR and high levels of the Nodal mimetic Activin-A (50-100 ng/ml) during Day 0-1 efficiently induced definitive endoderm, whereas CHIR supplemented with Activin-A at low levels (10 ng/ml) consistently improved cardiomyogenic efficiency, even when CHIR alone was ineffective. Moreover, co-induction using CHIR and low levels of Activin-A apparently increased the rate of cardiomyogenesis, as indicated by the initial appearance of rhythmically beating cells by Day 6 instead of Day 8. By contrast, co-induction with CHIR plus low levels (3-10 ng/ml) of Bmp4 during Day 0-1 consistently and strongly inhibited cardiomyogenesis. These findings, which demonstrate that cardiomyogenic efficacy is improved by optimizing levels of CHIR-induced growth factors when applied in accord with their sequence of endogenous expression, are consistent with the idea that Nodal (Activin-A) levels toggle the entry of cells into the endodermal or mesodermal lineages, while Bmp levels regulate subsequent allocation into mesodermal cell types.

UR - http://www.scopus.com/inward/record.url?scp=84923332744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923332744&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0118670

DO - 10.1371/journal.pone.0118670

M3 - Article

C2 - 25706534

AN - SCOPUS:84923332744

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0118670

ER -